JNJ

168.03

+1.28%↑

NVS

117.07

+0.85%↑

ABT

127.93

+1.35%↑

MDT

92.47

+0.6%↑

ELV.US

288.56

+1%↑

JNJ

168.03

+1.28%↑

NVS

117.07

+0.85%↑

ABT

127.93

+1.35%↑

MDT

92.47

+0.6%↑

ELV.US

288.56

+1%↑

JNJ

168.03

+1.28%↑

NVS

117.07

+0.85%↑

ABT

127.93

+1.35%↑

MDT

92.47

+0.6%↑

ELV.US

288.56

+1%↑

JNJ

168.03

+1.28%↑

NVS

117.07

+0.85%↑

ABT

127.93

+1.35%↑

MDT

92.47

+0.6%↑

ELV.US

288.56

+1%↑

JNJ

168.03

+1.28%↑

NVS

117.07

+0.85%↑

ABT

127.93

+1.35%↑

MDT

92.47

+0.6%↑

ELV.US

288.56

+1%↑

Search

CareDx Inc

Cerrado

SectorSalud

12.72 -0.55

Resumen

Variación precio

24h

Actual

Mínimo

12.5

Máximo

12.9

Métricas clave

By Trading Economics

Ingresos

-88M

-10M

Ventas

-1.9M

85M

P/B

Media del Sector

11.384

38.156

Margen de beneficio

-12.225

Empleados

644

EBITDA

-6.1M

-13M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 meses

+93.9% upside

Dividendos

By Dow Jones

Próximas Ganancias

6 ago 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-302M

710M

Apertura anterior

13.27

Cierre anterior

12.72

Noticias sobre sentimiento de mercado

By Acuity

59%

41%

329 / 375 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Neutral Evidence

CareDx Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

29 jul 2025, 23:57 UTC

Adquisiciones, fusiones, absorciones

EQT: To Spend Y407.82B for Tender Offer

29 jul 2025, 23:56 UTC

Adquisiciones, fusiones, absorciones

EQT: Tender Offer Price Is Y5,700 a Share

29 jul 2025, 23:54 UTC

Adquisiciones, fusiones, absorciones

EQT To Start Tender Offer for Fujitec

29 jul 2025, 23:50 UTC

Charlas de Mercado

Nikkei May Fall Amid Uncertainty Over Earnings, Domestic Politics -- Market Talk

29 jul 2025, 23:36 UTC

Charlas de Mercado

Gold Steady Ahead of FOMC Decision -- Market Talk

29 jul 2025, 22:57 UTC

Charlas de Mercado

Perseus May Step Up Capital Management at FY 2025 Result -- Market Talk

29 jul 2025, 22:50 UTC

Charlas de Mercado

Mondelez Warns of Price Increases in North America -- Market Talk

29 jul 2025, 22:44 UTC

Adquisiciones, fusiones, absorciones

St Barbara: Potential Divestment of Nova Scotia Ops to be Weighed in 1Q FY26

29 jul 2025, 22:41 UTC

Adquisiciones, fusiones, absorciones

St Barbara FY25 All-in Sustaining Cost A$4,582/Oz

29 jul 2025, 22:41 UTC

Adquisiciones, fusiones, absorciones

St Barbara 4Q All-in Sustaining Cost A$4,613/Oz

29 jul 2025, 22:35 UTC

Ganancias

IGO Maintains Nova Life of Mine Production Guidance

29 jul 2025, 22:35 UTC

Ganancias

IGO Expects FY 2026 Greenbushes Output of 1.50 Million-1.65 Million Tons

29 jul 2025, 22:35 UTC

Ganancias

IGO Expects FY 2026 Greenbushes Cash Costs of A$310-A$360/Ton

29 jul 2025, 22:34 UTC

Ganancias

IGO Expects Train 1 of Kwinana Refinery to Be Fully Impaired

29 jul 2025, 22:34 UTC

Ganancias

IGO Expects to Impair Kwinana Refinery Assets by A$70 Million-A$90 Million

29 jul 2025, 22:34 UTC

Charlas de Mercado
Ganancias

Mondelez Snack Demand Holding Up Better in Europe Than U.S. -- Market Talk

29 jul 2025, 22:33 UTC

Ganancias

IGO Had A$279.7 Million of Cash at End-June

29 jul 2025, 22:33 UTC

Ganancias

IGO 4Q Underlying Free Cash A$2.4 Million

29 jul 2025, 22:33 UTC

Ganancias

IGO FY Sales Revenue A$512.5 Million

29 jul 2025, 22:33 UTC

Ganancias

IGO 4Q Sales Revenue A$126.9 Million, Up 15% on 3Q

29 jul 2025, 22:32 UTC

Ganancias

IGO FY Nickel Production 17,173 Tons

29 jul 2025, 22:32 UTC

Ganancias

IGO 4Q Nickel Production 5,107 Tons, Up 22% on 3Q

29 jul 2025, 22:32 UTC

Ganancias

IGO 4Q Lithium Hydroxide Production 2,126 Tons, Up 36% on 3Q

29 jul 2025, 22:31 UTC

Charlas de Mercado
Ganancias

Global Equities Roundup: Market Talk

29 jul 2025, 22:31 UTC

Charlas de Mercado
Ganancias

Mondelez Sees Consumers Trading Down, Buying in Bulk -- Market Talk

29 jul 2025, 22:31 UTC

Ganancias

IGO 4Q Spodumene Cash Cost A$366/Ton, Up 7% on 3Q

29 jul 2025, 22:31 UTC

Ganancias

IGO FY Spodumene Production 1.48 Million Tons

29 jul 2025, 22:30 UTC

Ganancias

IGO 4Q Spodumene Production 340,000 Tons, Flat on 3Q

29 jul 2025, 22:30 UTC

Ganancias

IGO 4Q Underlying Ebitda A$62 Million

29 jul 2025, 22:22 UTC

Ganancias

Starbucks Abandons Mobile Order, Pickup-Only Stores -- WSJ

Comparación entre iguales

Cambio de precio

CareDx Inc Esperado

Precio Objetivo

By TipRanks

93.9% repunte

Estimación a 12 meses

Media 24.8 USD  93.9%

Máximo 28 USD

Mínimo 19 USD

De acuerdo con 5 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para CareDx Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

5 ratings

3

Comprar

2

Mantener

0

Vender

Puntuación técnica

By Trading Central

14.77 / 18.49Soporte y Resistencia

Corto Plazo

Neutral Evidence

Medio plazo

Strong Bearish Evidence

Largo Plazo

Weak Bearish Evidence

Sentimiento

By Acuity

329 / 375 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura bajista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de CareDx Inc

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.